NCT05882370View on ClinicalTrials.gov

TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

June 30, 2025

Study Completion Date

August 31, 2025

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

Cadonilimab

Patients were treated with TIPS plus Cadonilimab (10mg/kg, intravenously, d1, Q3W) to a maximum total cycle of 18 unless any evidence of disease progression or unacceptable side effects.

PROCEDURE

transjugular intrahepatic portosystemic shunt (TIPS)

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Fei Gao

OTHER